Lv1
80 积分 2022-05-10 加入
Spatial determinants of antibody-drug conjugate SHR-A1811 efficacy in neoadjuvant treatment for HER2-positive breast cancer
8天前
已完结
Inhibiting TROP2 in advanced non-small-cell lung cancer with sacituzumab govitecan, datopotamab deruxtecan, and sacituzumab tirumotecan: similarities and differences
29天前
已完结
Optimizing treatment for HER2-positive HR-positive breast cancer
1个月前
已完结
Amivantamab plus Lazertinib in Previously Untreated EGFR -Mutated Advanced NSCLC
1个月前
已完结
Diagnosis and Treatment of ALK Aberrations in Metastatic NSCLC
1个月前
已完结
Efficacy and safety of first-line lorlatinib versus crizotinib in patients with advanced, ALK-positive non-small-cell lung cancer: updated analysis of data from the phase 3, randomised, open-label CROWN study
1个月前
已完结
Molecular analysis of gastric cancer identifies subtypes associated with distinct clinical outcomes
2个月前
已完结
High risks adverse events associated with trastuzumab emtansine and trastuzumab deruxtecan for the treatment of HER2-positive/mutated malignancies: a pharmacovigilance study based on the FAERS database
2个月前
已完结
Early versus deferred use of CDK4/6 inhibitors in advanced breast cancer: circulating tumor DNA analysis of a randomized phase 3 trial
3个月前
已完结
Early versus deferred use of CDK4/6 inhibitors in advanced breast cancer
3个月前
已完结
皖公网安备34019202002308
